Survival from pancreatic cancer is poor because most cancers are diagnosed in the late
stages and there are no therapies to prevent the progression of precancerous pancreatic …

Pancreatic cancer is a highly aggressive malignancy that strongly resists extant treatments.
The failure of existing therapies is majorly attributed to the tough tumor microenvironment …

The K-ras mutation in pancreatic cancer can inhibit drug delivery and increase drug
resistance. This is exemplified by the therapeutic effect of PH-427, a small molecule inhibitor …

Developing new targeted therapy for pancreatic cancer is one of the major current
challenges in cancer research. KRAS mutations and miRNA dysregulation (eg miR-21-5p …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid tumors in the world.
Currently, there are no approved targeted therapies for PDAC. Mutations in Kirsten rat …

Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA
is addicted to the activity of the mutated KRAS oncogene which is considered so far an …

Pancreatic cancer (PC) stands as a most deadly malignancy due to few effective treatments
in the clinics. KRAS G12D mutation is a major driver for most PC cases, and silencing of …

Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of other
tumor types, such as colorectal adenocarcinoma, are driven by KRAS activation. However …

287 Background: Greater than 95% of pancreatic adenocarcinomas (PDACs) are driven by
KRAS activation; yet, despite decades of work, no RAS inhibitors have reached the clinic …

Survival from pancreatic cancer remains extremely poor, in part because this malignancy is
not diagnosed in the early stages, and precancerous pancreatic intraepithelial neoplasia …